Claims for Patent: 7,989,205

Summary for Patent: 7,989,205

Title:	Cell culture media, kits and methods of use
Abstract:	Albumin-supplemented and xenogeneic product-free cell culture media, cell culture media supplements, and cell culture media kits for the support of primary culture of normal non-hematopoietic cells of mesodermal origin suitable for both research and clinical applications.
Inventor(s):	Moscatello; David K. (Philadelphia, PA)
Assignee:	American Cryostem Corporation (Red Bank, NJ)
Application Number:	11/542,863
Patent Claims:	1. A cell culture medium for clinical growth of human adipose stromal cells for human clinical and therapeutic applications, said medium comprising: a basal medium suitable for mammalian cell culture; human albumin; growth-promoting amounts of human insulin, human transferrin, human recombinant epidermal growth factor, human recombinant platelet-derived growth factor-BB, human recombinant basic fibroblast growth factor; and additionally comprising L-ascorbic acid 2-phosphate. 2. The cell culture medium of claim 1 wherein the human albumin is a recombinant protein derived from the human albumin gene expressed in a prokaryotic or eukaryotic microbe. 3. The cell culture medium of claim 1 wherein the human insulin is a recombinant protein produced in a microorganism. 4. The cell culture medium of claim 1 wherein the human insulin is present in concentrations of between about 1 and 50 mg/l. 5. The cell culture medium of claim 1 wherein the human transferrin is present in concentrations of between about 1 and 50 mg/l. 6. The cell culture medium of claim 1 wherein the human transferrin is a recombinant protein produced in a microorganism. 7. The cell culture medium of claim 1 wherein the human albumin is human plasma- or serum-derived albumin or recombinant human albumin in concentrations of between about 0.5 and 10 g/100 ml. 8. The cell culture medium of claim 1 wherein the cell culture medium comprises recombinant human epidermal growth factor in concentrations of between about 2 and 50 ng/ml. 9. The cell culture medium of claim 1 wherein the cell culture medium comprises recombinant human platelet-derived growth factor-BB in concentrations of between about 2 and 20 ng/ml. 10. The cell culture medium of claim 1 wherein the cell culture medium comprises recombinant human basic fibroblast growth factor in concentrations of between about 0.1 to 100 ng/ml. 11. The cell culture medium of claim 1 wherein the cell culture medium comprises insulin-like growth factor 1 in concentrations of between about 0.1 to 100 ng/ml. 12. The cell culture medium of claim 1 wherein the cell culture medium comprises at least one of endothelin-1, endothelin-2 and endothelin-3 in concentrations of between about 0.01 to 100 ng/ml. 13. The cell culture medium of claim 1 wherein the cell culture medium comprises recombinant human hepatocyte growth factor in concentrations of between about 0.1 ng/ml to 100 ng/ml. 14. The cell culture medium of claim 1 further comprising 2-mercaptoethanol in concentrations of between about 50 and 500 micromolar. 15. The cell culture medium of claim 1 comprising L-ascorbic acid 2-phosphate in concentrations of between about 50 and 500 micromolar. 16. The cell culture medium of claim 1 comprising dexamethasone in concentrations of between 0.1 and 100 nanomolar. 17. The cell culture medium of claim 1 wherein the medium is suitable for cultivating research-grade cells, and wherein the medium further comprises human serum and contains no xenogeneic products. 18. The cell culture medium of claim 1 wherein the medium is suitable for cultivating clinical grade cells, and wherein the medium contains no serum or xenogeneic products. 19. A method of cultivating an human adipose stromal cells comprising the steps of (a) contacting the human adipose stromal cells with the cell culture medium of claim 1 and (b) cultivating the human adipose stromal cells under conditions suitable to support cultivation of human adipose stromal cells. 20. The method of claim 19 wherein step (b) comprises cultivating human adipose stromal cells in a culture vessel coated with adhesion-promoting substrata. 21. The method of claim 20 wherein the adhesion-promoting substrata comprises human fibronectin or functional fibronectin fragment with or without collagen. 22. The method of claim 21 wherein the fibronectin or functional fibronectin fragment substrate is from human plasma. 23. The method of claim 21 wherein the human fibronectin or functional fibronectin fragment is a recombinant protein derived from the human fibronectin gene or a fragment thereof expressed in a prokaryotic or eukaryotic microbe. 24. The method of claim 21 wherein the fibronectin or functional fibronectin fragment is added to the culture substrate at 0.5 to 20 micrograms per square centimeter of surface area. 25. The method of claim 19 wherein step (b) comprises using non-enzymatic neutral-buffered solutions containing at least one of ethylene glycol-bis(2-aminoethylether)-N,N,N',N'-tetraacetic acid or ethylene diamine tetraacetic acid and sodium salts thereof to remove cells from a culture substrate. 26. The method of claim 19 wherein the human adipose stromal cells are cultivated for human clinical or veterinary therapeutic purposes. 27. The method of claim 19 wherein the human adipose stromal cells are cultivated for in vitro research purposes.

Details for Patent 7,989,205

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	10/28/1982		2025-10-06
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	12/29/2015		2025-10-06
Eli Lilly And Company	HUMULIN R U-100	insulin human	Injection	018780	08/06/1998		2025-10-06
Eli Lilly And Company	HUMULIN R U-500	insulin human	Injection	018780	03/31/1994		2025-10-06